文献速递血管炎

系统性血管炎患者第三代QuantiFERON-TB Gold管内试验不确定结果率高

High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

这项单中心回顾性研究纳入38例未接受糖皮质激素或免疫抑制剂治疗的系统性血管炎患者,比较其QFT-GIT不确定结果率与其他两组患者。血管炎组因对植物血凝素A无反应导致的不确定结果率为21.1%,显著高于匿名对照组的7%(P=0.009),多变量分析显示系统性血管炎和高中性粒细胞与淋巴细胞比值是不确定结果的独立预测因素。

要点

  • 血管炎患者QFT-GIT不确定结果率为21.1%,显著高于匿名对照组的7%。
  • 系统性血管炎(OR 9.64)和高中性粒细胞与淋巴细胞比值(OR 1.70)是不确定结果的独立预测因素。
  • 研究对QFT-GIT在血管炎患者中排除潜伏结核的可靠性提出质疑。

核心结论

  • 系统性血管炎患者在接受免疫抑制治疗前QFT-GIT不确定结果率较高,提示该试验在此类人群中排除潜伏结核的可靠性存疑。

主要发现

  • 血管炎组因对植物血凝素A无反应导致的不确定结果率为21.1%,非血管炎炎症综合征组为7.5%(Fisher精确检验P=0.11),匿名对照组为7%(P=0.009)。
  • 血管炎组对植物血凝素A的反应显著低于其他组(Kruskal-Wallis检验P<0.0001),也显著低于非血管炎炎症综合征组(P=0.0015)。
  • 多变量分析显示系统性血管炎(OR 9.64 [1.14-81.3],P=0.037)和高中性粒细胞与淋巴细胞比值(OR 1.70 [1.21-2.37],P=0.002)是不确定结果的独立预测因素。
  • 1例QFT-GIT结果不确定的患者在因巨细胞动脉炎接受糖皮质激素治疗一年后发生活动性结核。

临床怎么用

  • 在系统性血管炎患者开始免疫抑制治疗前,应谨慎解读QFT-GIT不确定结果,不宜仅凭该试验排除潜伏结核。

局限性

  • 本研究为单中心回顾性研究,样本量较小,血管炎组仅38例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the frequency of QuantiFERON-TB Gold in-tube test® (QFT-GIT) indeterminate results due to no response to phytohaemagglutinin A stimulation in the control tube in vasculitis patients prior to immunosuppressant therapy; and to compare it with other groups of patients. METHODS: This was a single-centre, retrospective study. Patients and controls were included between 1 January 2008 and 31 December 2015. We assessed the rate of indeterminate results of the QFT-GIT in 38 patients with systemic vasculitis prior to any corticosteroid or immunosuppressant therapy, compared with 40 non-vasculitis patients with biological inflammatory syndrome, and 310 non-immunosuppressed patients matched for gender and age. RESULTS: Indeterminate results due to no response to phytohaemagglutinin A were more frequent in vasculitis patients (21.1%) compared with non-vasculitis patients with biological inflammatory syndrome (7.5%) (Fisher's exact test: P = 0.11) and to anonymized controls (7%) (P = 0.009). Responses to phytohaemagglutinin A were significantly lower in vasculitis patients compared with other groups (Kruskal-Wallis test: P < 0.0001) and compared with non-vasculitis patients with biological inflammatory syndrome (P = 0.0015). The multivariable analysis identified as independent predictors of an indeterminate result of the QFT-GIT: the presence of systemic vasculitis (odds ratio 9.64 [1.14-81.3], P = 0.037) and a high neutrophil-to-lymphocyte ratio (odds ratio 1.70 [1.21-2.37], P = 0.002). One patient with an indeterminate result of QFT-GIT developed active tuberculosis after one year of corticosteroid therapy for giant cell arteritis. CONCLUSION: Our results question the reliability of QFT-GIT to rule out latent tuberculosis in vasculitis patients at diagnosis, prior to immunosuppressant therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rousset S, Treiner E, Moulis G, et al. High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis. Rheumatology (Oxford). 2020. PMID: 31518431. doi:10.1093/rheumatology/kez390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。